VKTX

+ Watchlist + Portfolio

Viking Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $35.98
52-Week Range: $22.96 – $43.15
Market Cap: $4.01B
P/E (TTM): —
EPS (TTM): -4.67
Dividend Yield: —

Advanced Metrics

Price/Book: 9.82
PEG Ratio: —
Return on Equity: -88.85%
Return on Assets: -51.86%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.72
Debt/Equity: 0.01
Total Debt: $4.09M
Free Cash Flow: $-230.79M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $3.70B

VKTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$54.23M	$63.81M	$101.64M	$344.95M
Selling, General & Admin	$16.12M	$37.02M	$49.28M	$48.39M
Operating Expenses	$70.36M	$100.83M	$150.92M	$393.34M
Operating Income	-$70.36M	-$100.83M	-$150.92M	-$393.34M
EBITDA	-$70.06M	-$100.53M	-$150.57M	-$392.91M
Pretax Income	-$68.87M	-$85.89M	-$109.96M	-$359.64M
Net Income	-$68.87M	-$85.89M	-$109.96M	-$359.64M
Diluted EPS	-0.90	-0.91	-1.01	-3.19
Diluted Shares	76.83M	94.35M	109.04M	112.67M

VKTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$36.63M	$55.52M	$26.68M	$165.81M
Current Assets	$167.04M	$367.23M	$907.22M	$715.60M
Total Assets	$168.53M	$368.49M	$908.32M	$715.73M
Current Liabilities	$21.95M	$19.14M	$27.41M	$76.67M
Total Debt	$1.56M	$1.26M	$1.12M	$137.00K
Total Liabilities	$23.21M	$20.07M	$28.04M	$76.67M
Retained Earnings	-$292.05M	-$377.94M	-$487.91M	-$847.55M
Shareholders' Equity	$145.32M	$348.42M	$880.28M	$639.06M
Working Capital	$145.09M	$348.09M	$879.80M	$638.93M

VKTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$48.40M	-$73.38M	-$87.79M	-$278.69M
Free Cash Flow	-$48.40M	-$73.38M	-$87.79M	-$278.69M
Depreciation & Amortisation	$291.00K	$292.00K	$346.00K	$431.00K
Stock-Based Compensation	$8.67M	$16.75M	$29.71M	$40.82M
Investing Cash Flow	$54.75M	-$179.09M	-$553.37M	$341.39M
Financing Cash Flow	$4.16M	$271.38M	$612.46M	$76.44M
Share Repurchases	-$6.82M	$0.00	$0.00	—
Net Change in Cash	$10.52M	$18.91M	-$28.69M	$139.14M

VKTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$41.39M	$60.15M	$89.95M	$153.46M	$150.15M
Selling, General & Admin	$14.08M	$14.42M	$8.61M	$11.28M	$13.97M
Operating Expenses	$55.47M	$74.57M	$98.56M	$164.74M	$164.13M
Operating Income	-$55.47M	-$74.57M	-$98.56M	-$164.74M	-$164.13M
EBITDA	-$55.36M	-$74.46M	-$98.45M	-$164.64M	-$164.04M
Pretax Income	-$45.63M	-$65.56M	-$90.79M	-$157.66M	-$158.32M
Net Income	-$45.63M	-$65.56M	-$90.79M	-$157.66M	-$158.32M
Diluted EPS	-0.41	-0.58	-0.81	-1.38	-1.37
Diluted Shares	112.07M	112.13M	112.32M	114.00M	115.57M

VKTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$37.94M	$33.88M	$100.38M	$165.81M	$118.12M
Current Assets	$866.02M	$827.02M	$738.70M	$715.60M	$608.21M
Total Assets	$866.99M	$827.85M	$739.41M	$715.73M	$608.24M
Current Liabilities	$19.57M	$31.98M	$26.07M	$76.67M	$106.33M
Total Debt	$1.00M	$878.00K	$755.00K	$137.00K	$0.00
Total Liabilities	$20.07M	$32.39M	$26.39M	$76.67M	$106.33M
Retained Earnings	-$533.54M	-$599.10M	-$689.88M	-$847.55M	-$1.01B
Shareholders' Equity	$846.92M	$795.46M	$713.03M	$639.06M	$501.92M
Working Capital	$846.45M	$795.04M	$712.64M	$638.93M	$501.88M

VKTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$52.33M	-$47.06M	-$94.00M	-$85.29M	-$113.98M
Free Cash Flow	-$52.33M	-$47.06M	-$94.00M	-$85.29M	-$113.98M
Depreciation & Amortisation	$111.00K	$112.00K	$114.00K	$94.00K	$85.00K
Stock-Based Compensation	$11.35M	$13.55M	$7.34M	$8.59M	$10.34M
Investing Cash Flow	$63.24M	$42.51M	$160.03M	$75.61M	$54.19M
Financing Cash Flow	$349.00K	$507.00K	$480.00K	$75.10M	$12.08M
Net Change in Cash	$11.26M	-$4.05M	$66.50M	$65.42M	-$47.71M

Market Snapshot

About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. The company's pipeline includes drug candidates for non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, and other metabolic conditions. Viking focuses on small molecule therapeutics targeting nuclear receptors.